Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract

Inclusion Criteria:

* Recurrent or second upper aerodigestive tract carcinoma in an area previously irradiated at a dose of \>= 50 Gy
* Squamous cell carcinoma
* No grade III or IV sequels linked to the first radiation therapy (excepted radiation sequels of salivary glands)
* Relapse or second carcinoma (clinically invasive and/or lymph node recurrence \>= 3 cm and/or the association of a local and lymph node recurrence
* Oral cavity, pharynx, larynx (if rT4), cervical region (if \>3cm)
* No distant metastases confirmed by chest CT scan, abdominal ultrasound (or CT scan) in case of abnormal liver function, and bone scintigraphy in case of local symptoms
* Surgery in the previously irradiated region allowing a macroscopically adequate resection
* Surgery and vascular protection with a myocutaneous or free flap
* Interval \> = 6 months between the end of the first radiation treatment and surgery in the previously irradiated area
* Wound healing allowing reirradiation within an interval of 8 weeks after surgery in the previouly irradiated area.
* No participation in a clinical trial during the 30 days preceding inclusion
* Age between 18 et 70 years.
* Performance Status 0 or 1 according to WHO criteria.
* Hematological function : neutrophils \* 2 x 106/l, platelets : \* 100 x 106/l, hemoglobin : \* 10 g/dl (or 6.2 mmol/l)
* Liver function : total bilirubin (normal) ; ASAT (SGOT) and ALAT (SGPT) \* 2.5 \* upper limit of normal (ULN) in each centre ; alkaline phosphatases \* 5 \* ULN. Patients whose ASAT or ALAT levels \> 1.5 \* ULN associated with alkaline phosphatases \* 2.5 \* ULN are not eligible for the trial
* Renal function : serum creatinine \* 120 \*mol/l (1.4 mg/dl) ; if creatinine level is \> 120 \*mol/l, creatinine clearance should be \* 60 ml/min.
* Written consent of participants

Exclusion Criteria:

* Superficial recurrence not associated with a lymph node relapse, isolated lymph node recurrence measuring less than 3 cm
* Distant metastases
* Grade 3 or 4 sequels of first radiation therapy (excepted salivary gland sequels)
* Macroscopically inadequate surgery
* Delay in wound healing obliging reirradiation to be postponed beyond 8 weeks.
* \> Grade 3 Toxicity induced by chemotherapy administered during a previous treatment
* Hypersensitivity to Erbitux
* Concomitant severe comorbidities (non exhaustive list)
* Unstable cardiac comorbidity in spite of treatment.
* Neurological or psychiatric history such as dementia, convulsions.
* Severe uncontrolled infection
* Obstructive bronchopneumopathy which required hospitalisation during the year preceding inclusion.
* Factors (psychological, familial, social or geographic) likely to hinder patient compliance with the study protocol and follow-up are considered exclusion criteria. These factors should be discussed with the patient before enrollment in the trial
* Women who are pregnant, breast-feeding or of birthgiving age without effective contraception